Answers are grounded in this paper and cite their sources.
Explores neoadjuvant immunotherapy's impact on surgical needs in colorectal cancer, suggesting a shift in management.
Microsatellite unstable (MSI-H) colorectal cancers (CRC) are the hallmark of Lynch Syndrome. Advances in immunotherapy have yielded a change in the treatment of those cancers. Recent publications about neoadjuvant immunotherapy in CRC are triggering a high interest to use under the umbrella of achieving a complete clinical response. Although we do not know the extent of this response over time, avoiding surgical morbidity seems to be on the horizon for this subset of CRC.
No takes yet. Share an insight, caveat, or question.
Khalil et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: